Undisclosed mitochondrial protein component of mPTP (Protein A)

The undisclosed mitochondrial protein component of mPTP, often referred to as Protein A, is a novel, mitochondrially-localized protein that serves as an essential regulator of the mitochondrial permeability transition pore (mPTP). Identified by NRG Therapeutics, this protein is a key mediator of mitochondrial dysfunction in neurodegenerative diseases, where it is thought to be the site where toxic protein aggregates like TDP-43 and alpha-synuclein trigger pathological pore opening. When the mPTP opens, it leads to mitochondrial swelling, loss of membrane potential, and the release of mitochondrial DNA (mtDNA) into the cytoplasm, which activates the innate immune system and drives neuroinflammation. Small molecule inhibitors like NRG5051 target this protein to prevent pore opening and protect neuronal health. This approach is being developed as a disease-modifying therapy to slow or halt the progression of Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. The target is distinguished from historical mPTP targets like Cyclophilin D by its novel mechanism and potential for brain-penetrant, selective modulation.

Other names

Protein AmPTP regulatormPTP componentMitochondrial permeability transition pore regulator

Inhibition of the mitochondrial permeability transition pore (mPTP) by binding to a novel, undisclosed protein regulator (Protein A), thereby preventing pore opening, mitochondrial swelling, and the release of pro-inflammatory mitochondrial DNA.